- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05089123
The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old
Prospective, Multicenter, Double-blind, Randomized, Comparative Immunogenicity and Safety Trial of Flu-M [Inactivated Split Influenza Vaccine], Solution for Intramuscular Injection, 0.5 ml (FSUE SPbSRIVS FMBA), vs. Ultrix®, Solution for Intramuscular Injection, 0.5 ml (FORT LLC) in Volunteers Aged Over 60 Years
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The volunteers will include in the trial will divide into two groups:
Group 1: volunteers who will receive one dose of Flu-M, solution for intramuscular injection, 0.5 mL, intramuscularly.
Group 2: volunteers who will receive one dose of Ultrix®, solution for intramuscular administration, 0.5 mL, intramuscularly.
The trial include the following periods and visits:
Screening period (up to 7 days):
• Visit 0 (day -7...-1).
Vaccination period (up to 1 day):
• Visit 1 (day 1, randomization, blood collection for serological examination, vaccination).
Follow-up period (up to 28(+2) days):
- Visit 2 (day 3, organization of trials to assess safety);
- Visit 3 (day 7(+1), organization of trials to assess safety);
- Visit 4 (day 21(+2), organization of trials to assess safety, blood collection for serological study);
- Visit 5 (day 28(+2), organization of trials to assess safety, trial completion);
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Saint Petersburg, Russische Föderation
- LLC "Meditsinskie Tehnologii"
-
Saint Petersburg, Russische Föderation
- LLC "Strategicheskie Meditsinskie Sistemi"
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Presence of signed informed consent to participate in the trial.
- Volunteers (both male and female) over the age of 60 who could meet the Protocol requirements.
- Negative pregnancy test obtained from female volunteers with preserved childbearing potential.
- Consent to use adequate contraception methods (contraception methods with degree of reliability of more than 90%: a nonhormonal intrauterine device; a spermicide condom; a spermicide cervical cap; spermicide diaphragms) or total sexual abstinence during the clinical trial (until Visit 5 (day 28(+2)).
Exclusion Criteria:
- Allergic reactions to chicken protein or any previous influenza vaccination.
- Anamnestic data on the episodes of severe allergic reactions and/or diseases (anaphylaxis, Quincke's edema, polymorphic exudative erythema, serum disease etc.)
- Acute reaction (temperature above 38.5оС, edema and hyperemia over 5 cm in diameter at the injection site) or complications caused by previous administration of the drug.
- Previous vaccination 6 months before the start of the trial.
- History of leucosis, blood cancer, malignant oncological diseases.
- Guillain-Barré syndrome (acute polyneuropathy) in the medical history.
- Positive screening for HIV infection, B and C hepatitis, syphilis.
- Any confirmed or suspected immunosuppressive or immunodeficiency condition;
- Administration of immunoglobulin or blood products within the last three months before the study.
- Long-term use (more than 14 days) of immunosuppressants (including systemic corticosteroids, cytotoxic, radioactive preparations) or other immunomodulatory drugs for six months before the trial.
- Chronic diseases at the decompensation stage or in debilitating form, which can make it dangerous for the volunteer to take part in the trial.
- Progressive neurological disorders, dementia.
- Blood disorders which serve as a contradiction for intramuscular injection.
- History of alcohol or drug addiction.
- Pregnancy, breastfeeding in women with preserved reproductive performance.
- Current participation in another clinical trial or within the previous 3 months before the screening.
- Mental, physical and other problems which do not allow for appropriate assessment of own behavior and following the requirements set out in the trial protocol.
- Any other conditions which in the reasonable opinion of the clinical investigator complicate the participation of the volunteer in the trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Flu-M
160 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
|
Lösung zur intramuskulären Injektion, 0,5 ml
|
Aktiver Komparator: Ultrix
160 volunteers were vaccinated with the Ultrix (Inactivated split influenza vaccine)
|
Lösung zur intramuskulären Injektion, 0,5 ml
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Immunogenicity assessment
Zeitfenster: 21 days
|
Seroconversion rate defined as the percentage of subjects who have a pre-vaccination titer of influenza haemagglutinin antibody titer (HA titer) < 1:10 and a post-vaccination HA titer >1:40 or a pre-vaccination HA titer > 1:10 and at least a fourfold increase in post-vaccination HA titer vs. the baseline for each strain (A/H1N1, A/H3N2 and B)
|
21 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The percentage of subjects with protective titer of antibodies ≥ 1:40 on the 21(+2) day after the vaccination for each strain (A/H1N1, A/H3N2 and B).
Zeitfenster: 21 days
|
21 days
|
Increasing of geometric mean titer on the 21(+2) day against the value observed before the use of vaccine for each strain (A/H1N1, A/H3N2 and B)
Zeitfenster: 21 days
|
21 days
|
The percentage of volunteers with a pre-vaccination HA titer <1:10 and a post-vaccination HA titer >1:40 or a pre-vaccination HA titer > 1:10 and at least a fourfold increase in a post-vaccination HA titer vs. the baseline should be > 30%
Zeitfenster: 21 days
|
21 days
|
Increasing of geometric mean titer in > 2.0 times
Zeitfenster: 21 days
|
21 days
|
The percentage with protective antibody titer ≥ 1:40
Zeitfenster: 21 days
|
21 days
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- FM-2019-02
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Flu-M [Inaktivierter Split-Influenza-Impfstoff]
-
St. Petersburg Research Institute of Vaccines and...AbgeschlossenGrippe | Grippe, MenschRussische Föderation
-
St. Petersburg Research Institute of Vaccines and...Abgeschlossen
-
St. Petersburg Research Institute of Vaccines and...AbgeschlossenGrippeRussische Föderation
-
St. Petersburg Research Institute of Vaccines and...AbgeschlossenGrippe, Mensch | Impfung; Infektion | ImpfungenRussische Föderation
-
St. Petersburg Research Institute of Vaccines and...Abgeschlossen
-
St. Petersburg Research Institute of Vaccines and...Abgeschlossen
-
St. Petersburg Research Institute of Vaccines and...AbgeschlossenGrippe, Mensch | Impfung; Infektion | ImpfungenRussische Föderation
-
St. Petersburg Research Institute of Vaccines and...RekrutierungImpfstoffreaktion | Grippe | Grippe, Mensch | Influenza-VirusinfektionenRussische Föderation